The relevance of PD-1/PD-L1 as a therapeutic target in MPN has now been described, but the question of the efficacy of blockade therapies remains and the mechanisms involved in the process also need to be clarified. The gene discussed is PDCD1; the disease is myeloproliferative neoplasm.